Blood Apelin-36 Level in Patients with Depression

Abstract

Abstract Aim: Major Depressive Disorder is an important health problem leading to significant disability. Biochemical parameters that can be used in the diagnosis and follow-up of Major Depressive Disorders severity are important for clinicians. The aim of our study was to investigate blood apelin levels in patients with Major Depressive Disorder as a marker for disease severity and diagnosis. Materials and Methods: The study included 30 patients diagnosed with Major Depressive Disorder and 31 healthy controls. Hamilton Depression Scale was applied to the patient group. Blood apelin-36 levels were measured in both groups. Results: Plasma apelin-36 level was 0.363±0.102 ng/ml (min-max: 0.173-0.611) in the patient group and 1.140±0.738 ng/ml (min-max: 0.323-2.547) in the healthy control group. Blood apelin-36 level of the patient group was statistically significantly lower than that of the healthy control group (p<0.001). Conclusion: Blood apelin levels were found to be low in patients with Major Depressive Disorder. Apelin is an endogenous peptide with important physiological roles and looks promising as a biomarker. It’s utility for the diagnosis and follow-up of mood disorders requires further investigation. In this respect, our research contributes to the literature.

Keywords

• Depression
• Apelin
• Mood Disorders

Kaynakça

1. 1. Li X, Zhang X, Li F, linxi C, Lanfang L, Xuping Q, et al. 14-3-3 mediates apelin-13 induced enhancement of adhesion of monocytes to human umbilical vein endothelial cells. Acta Biochim Biophys Sin 2010:15;42(6):403-9.
2. 2. Galanth C, Hus-Citharel A, Li B, Liorens-Cortes C. Apelin in the control of body fluid homeostasis and cardiovascular function. Curr Pharm Des 2012;18(6):789-98.
3. 3. Habata Y, Fujii R, Hosova M, Fukusumi S, Kawamata Y, Hinuma S, et al. Apelin the natural ligand of the orphan receptor APJ is abundantly secreted in the colostrum. Biochim Biophys Acta 1999;1452(1):123-9.
4. 4. Smith TP, Schlenz AM, Schatz JC, Maitra R, Sweitzer SM. Modulation of pain in the pediatric sicle cell disease: understanding balance between endothelin mediated vasoconstriction and apelin mediated vasodilation. Blood Cell Mol Dis 2015;54(2):155-9.
5. 5. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005;107(2):198-211.
6. 6. Newson MJ, Roberts EM, Pope GR, Lolait SJ, O’Carroll AM. The effects of apelin on hypothalamic-pituitary- adrenal axis neuroendocrine function are mediated through corticotrophin releasing factor and vasopressin dependent mechanisms. J Endocrinol 2009;202(1):123-9.
7. 7. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146(4):1764-71.
8. 8. Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E, Alhava E, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005;130(1-2):7-13.

9. 9. Swaab DF, BaoAM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005;4(2):141-94.
10. 10. Singh M. Mood, food and obesity. Front Psycol 2014;5:925.
11. 11. Bali A, Jaggi AS. An integrative review on role and mechanisms of ghrelin in stress, anxiety and depression. Curr Drug Targets 2016;17(5):495-507.
12. 12. Ari M, Ozturk OH, Bez Y, Oktar S, Erduran D. High plasma nesfatin-1 level in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(2):497-500.
13. 13. Lu XY. The leptin hypothesis of depression: a potential link between mood disorder and obesity? CurrOpin Pharmacol 2007;7(6):648-52.
14. 14. Garcia FD, Coquerel Q, do Rego JC, Cravezic A, Bole-Feysot C, Kiive E, et al. Anti-neuropeptide Y plasma immunoglobulins in relation to mood and appetite in depressive disorder. Psychoneuroendocrinology 2012;37(9):1457-67.
15. 15. Telegdy G, Jaszberenyi. Transmitter mediation of the anxiolytic action of apelin-13 in male mice. Behav brain Res 2014;263:198-202.
16. 16. Akdemir A, Orsel SD, Dag I, Turkcapar H, Iscan N, Ozbay H. Hamilton depresyon degerlendirme olceginin gecerliligi ve klinikte kullanimi. Psikiyatri psikoloji ve psikofarmakoloji dergisi 1996;4:251-9.
17. 17. Sunter D, Hewson AK, Dickson SL. Intracerebroventricular injection of apelin-13 reduces food intake in the rat. Neurosci Lett 2003;353:1-4.
18. 18. Spinazzi R, andreis PG, Rossi GP, Nussdorfer GG. Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev 2006;58(1):46-57.
19. 19. Spencer SJ, Xu L, Clarke MA, Lemus M, Reichenbach A, Geenen B, et al. Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress. Biol Psychiatry 2012;72(6);457-65.
20. 20. Brundin L, Bjorkqvist M, Petersen A, Traskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol 2007;17(9):573-9.
21. 21. Holmes A, Heiling M, Rupniak NM, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorder. Trends Pharmacol Sci 2003;24(11):580-8.
22. 22. Xin Q, Cheng B, Pan Y, Liu H, Yang C, Chen J, et al. Neuroprotective effects of apelin-13 on experimental ishchemic stroke through suppression of inflammation. Peptides 2015;63:55-62.
23. 23. Cheng B, Chen J, Bai B, Xin Q. Neuroprotection of apelin and its signaling pathway. Peptides 2012;37(1):171-3.
24. 24. Yan XG, Cheng BH, Wang X. Lateral intracerebroventricular injection of Apelin -13 inhibits apoptsis after cerebral ischemia/reperfusion injury. Neural Regen Res 2015;10(5):766-71.
25. 25. Cook DR, Gleichman AJ, Cross SA, Doshi S, Ho W, Jordan-Sciutto KL, et al. . NMDA receptor modulation by the neuropeptide apelin: implications for excitotoxic injury. J Neurochem 2011;118:1113–23.
26. 26. Czeh B, Lucassen P. What cause the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptsis implicated? Eur Arch Psychiatry Clin Neurosci 2007;257(5):250-60.
27. 27. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness:stress and depression. Dialogues Clin Neurosci 2009;11(3):239-255.
28. 28. Castren E, Rantamaki T. Neurotrophins in depression and antidepressant effects. Novartis Found Symp 2008;289:43-52.
29. 29. Fornaro M, Escelsior A, Rocchi G, Conio B, Magioncalda P, Marozzi V, et al. BDNF plasma levels variations in major depressed patients receiving duloxetine. Neurol Sci 2015;36(5):729-34.
30. 30. Kopczak A, Stalla GK, Uhr M, Lucae S, Hennings J, Ising M, et al. IGF-I in major depression and antidepressant treatment response. Eur Neuropsychopharmacol 2015;25(6):864-72.